Trial Profile
A Phase II Study Of SB939 In Patients With Recurrent Or Metastatic Castration Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Pracinostat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 19 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 31 Jul 2013 Planned end date changed from 1 Nov 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.